ROCKET PHARMACEUTICALS, INC.

RCKT

ROCKET PHARMACEUTICALS, INC.

RCKT

Insider Sentiment (TTM):

Last Purchase:2026-01-02Last Sale:2026-05-21Shares Purchased (TTM):20,000Shares Sold (TTM):160,985

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:95,316,337Shares Outstanding:112,134,059Institutional Ownership Pct.:85.00%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	225	50	78	76	33	50	164	66	39	35	56	226
Short Term Investments	59	95	111	147	239	268	209	170	240	295	317	212
Prepaid Expense And Other Assets Current	6	5	4	5	6	6	6	6	14	15	5	10
Assets Current	290	150	193	228	277	324	378	242	293	345	378	447
Property Plant And Equipment Net	25	27	28	30	33	35	37	39	40	39	39	37
Goodwill	39	39	39	39	39	39	39	39	39	39	39	39
Intangible Assets Net Excluding Goodwill	25	25	25	25	25	25	25	25	25	25	25	25
Restricted Cash Equivalents Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Deposits Assets Noncurrent	0	0	0	1	1	1	1	1	0	1	1	1
Operating Lease Right Of Use Asset	3	3	3	4	4	4	4	4	5	5	4	4
Long Term Investments	-	-	-	-	-	-	0	0	0	0	34	0
Finance Lease Right Of Use Asset	-	40	40	41	41	42	42	43	43	44	45	45
Assets	423	285	330	368	421	471	528	394	446	499	566	599
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	28	22	27	28	41	32	38	37	35	30	46	31
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Finance Lease Liability Current	-	2	2	2	2	2	2	2	2	2	2	2
Liabilities Current	31	24	30	31	43	35	41	40	38	33	49	33
Operating Lease Liability Noncurrent	2	2	3	3	3	3	3	3	4	4	3	3
Finance Lease Liability Noncurrent	-	19	19	19	19	19	19	19	19	19	19	19
Other Liabilities Noncurrent	1	1	1	1	1	1	1	1	1	2	3	2
Liabilities	54	47	53	54	67	59	64	64	62	58	74	58
Stockholders Equity
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Treasury Stock Common Value	-	-	-	-	-	-	-	-	-	-	0	0
Additional Paid In Capital	1,733	1,726	1,717	1,711	1,702	1,691	1,680	1,486	1,475	1,462	1,451	1,440
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	0	0	-0	-0	0	-1
Retained Earnings Accumulated Deficit	-1,366	-1,489	-1,441	-1,399	-1,348	-1,279	-1,218	-1,158	-1,091	-1,021	-959	-900
Stockholders Equity	369	238	277	314	354	412	463	330	385	442	493	541
Liabilities And Stockholders Equity	423	285	330	368	421	471	528	394	446	499	566	599
Series A Convertible Preferred Shares	-	0	0	0	0	0	0	0	0	0	0	0
Series B Convertible Preferred Shares	-	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	180	180	180	180	180	180	180	180	180	120	180	120
Common Stock Shares Issued	110	109	108	108	108	107	106	91	91	91	90	90
Shares Outstanding	110	109	108	108	108	107	106	91	91	91	90	90
Treasury Stock Common Shares	-	-	-	-	-	-	-	-	-	-	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-16.35%	-11.44%	-13.08%	-	-	-	-	-	-	-	-	-
2025	-64.35%	-64.06%	-55.40%	6.15%	5.50%	24.60%	5.88%	7.74%	15.17%	-8.61%	-13.69%	-28.26%
2024	-8.73%	-7.83%	8.43%	-6.36%	-8.30%	-15.35%	-16.58%	-31.88%	-37.91%	-10.32%	-32.66%	-30.85%
2023	-	-	-	-	-	-	14.41%	46.41%	38.01%	-11.48%	-25.83%	-26.42%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.24	6.12	6.38	7.30	6.39	9.19	9.30	6.05	7.79	10.47	7.80	13.35
Quick Ratio	9.06	5.90	6.25	7.15	6.26	9.01	9.15	5.89	7.42	10.02	7.69	13.06
Working Capital	258.23M	125.36M	162.53M	196.51M	233.76M	289.18M	337.50M	201.77M	255.13M	312.20M	329.72M	413.39M
Leverage & Debt
Debt to Equity	0.15	0.20	0.19	0.17	0.19	0.14	0.14	0.19	0.16	0.13	0.15	0.11
Interest Coverage TTM	-101.29	-114.10	-122.55	-132.46	-141.69	-143.20	-144.86	-145.40	-143.43	-141.02	-138.48	-141.73
Debt Ratio	0.13	0.17	0.16	0.15	0.16	0.13	0.12	0.16	0.14	0.12	0.13	0.10
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.15	-1.87	-2.01	-2.16	-2.32	-2.34	-2.73	-2.74	-2.70	-2.67	-2.92	-3.06
Free Cash Flow Per Share TTM	-1.51	-1.60	-1.71	-1.82	-1.86	-1.93	-2.27	-2.15	-2.24	-2.24	-2.52	-2.86
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-93.30%	-18.85%	-13.77%	-6.65%	1.60%	3.49%	5.35%	2.15%	1.91%	5.10%	10.70%	26.72%
EPS Growth (1Y)	-93.40%	-20.33%	-26.43%	-21.22%	-14.21%	-12.06%	-6.65%	-10.35%	-12.52%	-10.74%	-10.20%	1.54%
Valuation Metrics
P/E TTM	-22.37	-1.92	-1.75	-1.51	-1.06	-2.85	-4.61	-6.74	-7.97	-10.11	-10.25	-6.70
P/B TTM	1.05	1.69	1.41	1.16	0.77	1.78	2.57	5.27	5.25	5.71	5.11	3.13
Market Cap	385.93M	401.44M	390.04M	363.72M	272.00M	734.32M	1.19B	1.74B	2.02B	2.52B	2.52B	1.69B
Enterprise Value	160.08M	371.76M	332.42M	307.68M	259.08M	704.40M	1.19B	1.69B	2.00B	2.50B	2.48B	1.49B
Calculated Values
Free Cash Flow TTM	-170.50M	-179.90M	-190.56M	-202.89M	-206.11M	-212.85M	-215.59M	-202.32M	-210.43M	-209.67M	-211.35M	-236.39M
Net Debt	-225.85M	-29.68M	-57.62M	-56.04M	-12.92M	-29.92M	-190.00K	-45.74M	-18.77M	-15.47M	-36.13M	-205.92M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-21Sale

Owner: Shah, Gaurav

Title: CEO

Shares: 55,684

Price/Share: $3.09

Value: $172,063.56

Shares Owned: 1,061,724

Relationship: Officer

Ownership: Direct

2026-05-19Sale

Owner: Militello, John

Title: See Remarks

Shares: 384

Price/Share: $3.01

Value: $1,155.84

Shares Owned: 89,780

Relationship: Officer

Ownership: Direct

2026-05-19Sale

Owner: Wilson, Martin

Title: General Counsel

Shares: 662

Price/Share: $3.01

Value: $1,992.62

Shares Owned: 677,977

Relationship: Officer

Ownership: Direct

2026-05-19Sale

Owner: Shah, Gaurav

Title: CEO

Shares: 2,409

Price/Share: $3.01

Value: $7,251.09

Shares Owned: 1,040,918

Relationship: Officer

Ownership: Direct

2026-05-13Sale

Owner: Militello, John

Title: See Remarks

Shares: 855

Price/Share: $3.61

Value: $3,086.55

Shares Owned: 90,164

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-21	Shah, Gaurav	Officer	CEO	Direct	Sale	55,684	3.09	$172,063.56	1,061,724	4
2026-05-19	Militello, John	Officer	See Remarks	Direct	Sale	384	3.01	$1,155.84	89,780	4
2026-05-19	Wilson, Martin	Officer	General Counsel	Direct	Sale	662	3.01	$1,992.62	677,977	4
2026-05-19	Shah, Gaurav	Officer	CEO	Direct	Sale	2,409	3.01	$7,251.09	1,040,918	4
2026-05-13	Militello, John	Officer	See Remarks	Direct	Sale	855	3.61	$3,086.55	90,164	4
2026-05-13	Wilson, Martin	Officer	General Counsel	Direct	Sale	3,361	3.61	$12,133.21	678,639	4
2026-05-13	Shah, Gaurav	Officer	CEO	Direct	Sale	2,728	3.61	$9,848.08	1,043,327	4
2026-05-07	Chaudhuri, Sarbani	Officer	See Remarks	Direct	Sale	17,650	3.84	$67,776.00	267,510	4
2026-02-18	Shah, Gaurav	Officer	CEO	Direct	Sale	5,990	3.34	$20,006.60	1,046,055	4
2026-02-18	Wilson, Martin	Officer	General Counsel	Direct	Sale	1,376	3.34	$4,595.84	682,000	4
2026-02-18	Militello, John	Officer	See Remarks	Direct	Sale	1,157	3.34	$3,864.38	91,019	4
2026-02-13	Wilson, Martin	Officer	General Counsel	Direct	Sale	12,253	3.31	$40,557.43	683,376	4
2026-02-13	Shah, Gaurav	Officer	CEO	Direct	Sale	12,279	3.31	$40,643.49	1,052,045	4
2026-02-13	Militello, John	Officer	See Remarks	Direct	Sale	3,726	3.31	$12,333.06	92,176	4
2026-01-02	Bjork, Elisabeth	Director	-	Direct	Purchase	10,000	3.44	$34,400.00	50,000	4
2025-11-18	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	6,276	2.98	$18,702.48	778,296	4
2025-11-18	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	2,545	2.98	$7,584.10	299,064	4
2025-11-18	Wilson, Martin	Officer	General Counsel	Direct	Sale	1,646	2.98	$4,905.08	383,816	4
2025-11-18	Militello, John	Officer	See Remarks	Direct	Sale	1,086	2.98	$3,236.28	65,920	4
2025-10-14	Militello, John	Officer	See Remarks	Direct	Sale	28,918	3.97	$114,804.46	67,006	4
2025-08-27	Bjork, Elisabeth	Director	-	Direct	Purchase	10,000	3.41	$34,100.00	40,000	4
2025-08-19	Wilson, Martin	Officer	General Counsel	Direct	Sale	588	3.00	$1,764.00	135,462	4
2025-08-19	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	805	3.00	$2,415.00	221,609	4
2025-08-19	Militello, John	Officer	See Remarks	Direct	Sale	361	3.00	$1,083.00	55,924	4
2025-08-14	Militello, John	Officer	See Remarks	Direct	Sale	7,043	3.02	$21,269.86	56,984	4
2025-08-14	Wilson, Martin	Officer	General Counsel	Direct	Sale	12,109	3.02	$36,569.18	137,054	4
2025-08-14	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	11,161	3.02	$33,706.22	224,094	4
2025-07-03	Ondrey, Aaron	Officer	Chief Financial Officer	Direct	Sale	1,477	2.88	$4,253.76	128,173	4
2025-05-20	Patel, Kinnari	Officer	See Remarks	Direct	Sale	767	6.45	$4,947.15	441,927	4
2025-05-20	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	2,253	6.45	$14,531.85	786,806	4
2025-05-20	Militello, John	Officer	See Remarks	Direct	Sale	357	6.45	$2,302.65	64,027	4
2025-05-20	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	801	6.45	$5,166.45	235,255	4
2025-05-20	Wilson, Martin	Officer	General Counsel	Direct	Sale	587	6.45	$3,786.15	149,163	4
2025-05-16	Patel, Kinnari	Officer	See Remarks	Direct	Sale	1,409	6.53	$9,200.77	442,694	4
2025-05-16	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	1,582	6.53	$10,330.46	236,056	4
2025-05-16	Militello, John	Officer	See Remarks	Direct	Sale	655	6.53	$4,277.15	64,384	4
2025-05-16	Wilson, Martin	Officer	General Counsel	Direct	Sale	946	6.53	$6,177.38	149,750	4
2025-05-16	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	3,621	6.53	$23,645.13	789,059	4
2025-04-22	Militello, John	Officer	See Remarks	Direct	Sale	718	7.16	$5,140.88	65,039	4
2025-04-10	Shah, Gaurav	Director,Officer	CEO	Direct	Purchase	20,000	5.08	$101,600.00	792,680	4
2025-04-09	Patel, Kinnari	Officer	See Remarks	Indirect	Purchase	21,099	4.70	$99,165.30	26,774	4
2025-04-04	Ondrey, Aaron	Officer	Chief Financial Officer	Direct	Sale	7,489	5.29	$39,616.81	129,650	4
2025-02-25	Schwartz, Jonathan David	Officer	See Remarks	Direct	Sale	6,532	10.58	$69,108.56	237,638	4
2025-02-21	Militello, John	Officer	See Remarks	Direct	Sale	2,737	10.58	$28,957.46	65,757	4
2025-02-21	Patel, Kinnari	Officer	See Remarks	Direct	Sale	6,078	10.58	$64,305.24	444,103	4
2025-02-21	Wilson, Martin	Officer	General Counsel	Direct	Sale	3,222	10.58	$34,088.76	150,696	4
2025-02-21	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	16,303	10.58	$172,485.74	772,680	4
2025-01-23	Militello, John	Officer	See Remarks	Direct	Sale	896	10.38	$9,300.48	48,414	4
2024-11-21	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	11,091	13.05	$144,737.55	707,328	4
2024-11-21	Militello, John	Officer	See Remarks	Direct	Sale	1,224	13.05	$15,973.20	49,310	4
2024-11-21	Patel, Kinnari	Officer	See Remarks	Direct	Sale	4,588	13.05	$59,873.40	392,395	4
2024-11-21	Wilson, Martin	Officer	General Counsel	Direct	Sale	1,175	13.05	$15,333.75	63,560	4
2024-10-31	Militello, John	Officer	See Remarks	Direct	Sale	917	16.63	$15,249.71	50,534	4
2024-10-31	White, Mark Andrew	Officer	See Remarks	Direct	Sale	3,080	16.63	$51,220.40	69,140	4
2024-08-16	Wilson, Martin	Officer	General Counsel	Direct	Sale	1,027	18.50	$18,999.50	64,735	4
2024-08-16	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	9,650	18.50	$178,525.00	718,419	4
2024-08-16	Patel, Kinnari	Officer	See Remarks	Direct	Sale	3,989	18.50	$73,796.50	396,983	4
2024-08-16	Militello, John	Officer	See Remarks	Direct	Sale	1,064	18.50	$19,684.00	51,451	4
2024-07-22	Militello, John	Officer	See Remarks	Direct	Sale	812	23.02	$18,692.24	52,515	4
2024-07-08	White, Mark Andrew	Officer	See Remarks	Direct	Sale	3,026	20.40	$61,730.40	72,220	4
2024-05-16	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	9,790	23.35	$228,596.50	728,069	4
2024-05-16	Wilson, Martin	Officer	General Counsel	Direct	Sale	1,048	23.35	$24,470.80	65,762	4
2024-05-16	Patel, Kinnari	Officer	See Remarks	Direct	Sale	4,046	23.35	$94,474.10	400,972	4
2024-05-16	Militello, John	Officer	See Remarks	Direct	Sale	1,079	23.35	$25,194.65	53,327	4
2024-04-22	Militello, John	Officer	See Remarks	Direct	Sale	833	22.87	$19,050.71	54,406	4
2024-04-15	Southwell, David P	Director	-	Direct	Sale	10,000	24.05	$240,500.00	114,784	4
2024-04-08	White, Mark Andrew	Officer	See Remarks	Direct	Sale	12,532	24.64	$308,788.48	75,226	4
2024-03-21	Militello, John	Officer	See Remarks	Direct	Sale	2,490	28.10	$69,969.00	55,239	4
2024-03-21	Makker, Gotham	Director	-	Indirect	Sale	274,000	28.43	$7,789,820.00	365,912	4
2024-03-21	Makker, Gotham	Director	-	Indirect	Sale	274,000	28.43	$7,789,820.00	365,912	4/A
2024-02-29	Militello, John	Officer	See Remarks	Direct	Sale	10,000	29.85	$298,500.00	21,517	4
2024-02-29	Wilson, Martin	Officer	General Counsel	Direct	Sale	4,100	29.33	$120,253.00	18,680	4
2024-02-16	Patel, Kinnari	Officer	See Remarks	Direct	Sale	7,132	29.84	$212,818.88	238,346	4
2024-02-16	Wilson, Martin	Officer	General Counsel	Direct	Sale	3,576	29.84	$106,707.84	6,136	4
2024-02-16	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	20,272	29.84	$604,916.48	554,762	4
2024-02-16	Militello, John	Officer	See Remarks	Direct	Sale	3,238	29.84	$96,621.92	13,195	4
2024-01-22	Militello, John	Officer	See Remarks	Direct	Sale	638	27.20	$17,353.60	10,159	4
2023-11-15	Makker, Gotham	Director	-	Indirect	Sale	20,000	22.53	$450,600.00	1,296,497	4
2023-10-20	Militello, John	Officer	See Remarks	Direct	Sale	564	17.06	$9,621.84	8,760	4
2023-09-29	Makker, Gotham	Director	-	Indirect	Sale	4,677	21.14	$98,871.78	1,316,497	4
2023-08-17	Militello, John	Officer	See Remarks	Direct	Sale	284	15.47	$4,393.48	5,570	4
2023-08-17	Shah, Gaurav	Director,Officer	CEO	Direct	Sale	4,767	15.47	$73,745.49	524,854	4
2023-08-17	Patel, Kinnari	Officer	See Remarks	Direct	Sale	1,534	15.47	$23,730.98	216,448	4
2023-07-20	Militello, John	Officer	See Remarks	Direct	Sale	573	19.03	$10,904.19	7,129	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

85.00%

Inst. Shares: 95,316,337

Shares Outstanding: 112,134,059

2025-12-31

80.70%

Inst. Shares: 89,671,983

Shares Outstanding: 111,123,770

2025-09-30

85.24%

Inst. Shares: 95,099,929

Shares Outstanding: 111,571,136

2025-06-30

83.15%

Inst. Shares: 92,309,964

Shares Outstanding: 111,019,647

2025-03-31

94.05%

Inst. Shares: 103,547,302

Shares Outstanding: 110,093,461

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	95,316,337	112,134,059	85.00%
2025-12-31	89,671,983	111,123,770	80.70%
2025-09-30	95,099,929	111,571,136	85.24%
2025-06-30	92,309,964	111,019,647	83.15%
2025-03-31	103,547,302	110,093,461	94.05%
2024-12-31	105,482,059	94,807,773	111.26%
2024-09-30	88,620,396	94,158,491	94.12%
2024-06-30	87,523,844	93,746,243	93.36%
2024-03-31	88,700,920	93,549,884	94.82%
2023-12-31	84,623,029	84,009,004	100.73%
2023-09-30	85,555,554	82,636,120	103.53%
2023-06-30	70,600,634	80,472,362	87.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ROCKET PHARMACEUTICALS, INC. (RCKT) — SEC Financial Statements & Analysis

ROCKET PHARMACEUTICALS, INC. (RCKT) is a pharmaceutical preparations company, incorporated in DE. ROCKET PHARMACEUTICALS, INC. trades on Nasdaq as: RCKT, RCKTW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ROCKET PHARMACEUTICALS, INC. reported a Debt-to-Equity ratio of 0.15x, a Price-to-Book (P/B) ratio of 1.05x (TTM), at a market cap of $385.93M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.15x
P/B TTM: 1.05x
Market Cap: $385.93M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ROCKET PHARMACEUTICALS, INC. in?

ROCKET PHARMACEUTICALS, INC. (RCKT) operates in the Pharmaceutical Preparations industry.

What is RCKT's market cap?

ROCKET PHARMACEUTICALS, INC. (RCKT) has a market capitalization of $385.93M as of 2026-06-30.

What exchange does RCKT trade on?

ROCKET PHARMACEUTICALS, INC. (RCKT) trades on the Nasdaq.

Where is ROCKET PHARMACEUTICALS, INC. incorporated?

ROCKET PHARMACEUTICALS, INC. is incorporated in DE.